Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases. Eiger's lead product candidate, avexitide, is a well characterized, first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Avexitide is the only drug in development for PBH with Breakthrough Therapy designation from the FDA. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com. For our social media and community guidelines, including information on how to report adverse events, please visit www.eigerbio.com/social-media-guidelines/
Looking for a particular Eiger BioPharmaceuticals employee's phone or email?
Eiger BioPharmaceuticals Questions
The Eiger BioPharmaceuticals annual revenue was $11.2 million in 2026.
Sarah Mathieson is the Senior Vice President, Head of Corporate Affairs of Eiger BioPharmaceuticals.
16 people are employed at Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals is based in Palo Alto, California.
The NAICS codes for Eiger BioPharmaceuticals are [541, 54, 3254, 32, 325, 32541].
The SIC codes for Eiger BioPharmaceuticals are [28, 283, 87, 873].
Top Eiger BioPharmaceuticals Employees
-
25
-
23
-
Eldon Mayer
Executive Vice President and Chief Commercial Officer at Eiger BioPharmaceuticals
Chebeague Island, ME, US14 -
Matthew Bys
Senior Director, Operations at Eiger BioPharmaceuticals
San Francisco, CA, US25
Related Companies
